Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.89 |
| ▸ | BTK | Q06187 | 8/20 | 0.89 |
| ▸ | ABL1 | P00519 | 5/20 | 0.74 |
| ▸ | EGFR | P00533 | 5/20 | 0.74 |
| ▸ | HCK | P08631 | 5/20 | 0.74 |
| ▸ | SRC | P12931 | 5/20 | 0.74 |
| ▸ | KDR | P35968 | 5/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.74 |
| ▸ | MTOR | P42345 | 5/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.74 |
| ▸ | PRKDC | P78527 | 5/20 | 0.74 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.74 |
| ▸ | ATR | Q13535 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655459 | 0.94 | PIK3CD (1.00) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655246 | 0.91 | PIK3CD (0.75) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655620 | 0.90 | PIK3CD (0.74) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655979 | 0.89 | PIK3CD (0.89) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655609 | 0.89 | PIK3CD (0.89) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655507 | 0.89 | PIK3CD (0.89) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16656036 | 0.88 | PIK3CD (0.69) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16665780 | 0.88 | PIK3CD (0.69) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655615 | 0.87 | ATR (0.76) | PIK3CDBTKABL1EGFRHCK | |
| SCHEMBL16655997 | 0.87 | PIK3CD (0.80) | PIK3CDBTKABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885BTK 1/4885ABL1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.